{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:42:15Z","timestamp":1786963335703,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Wassink Hesp Foundation","award":["Wassink Hesp Foundation"],"award-info":[{"award-number":["Wassink Hesp Foundation"]}]},{"DOI":"10.13039\/100014476","name":"Pfizer Pharmaceuticals","doi-asserted-by":"publisher","award":["88250917"],"award-info":[{"award-number":["88250917"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07557-9","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T03:43:25Z","timestamp":1760067805000},"page":"1836-1846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-2407","authenticated-orcid":false,"given":"Francesca Rita","family":"Ogliari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-9169","authenticated-orcid":false,"given":"Mandy","family":"Jongbloed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-2897","authenticated-orcid":false,"given":"Rianne D. W.","family":"Vaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-9733","authenticated-orcid":false,"given":"Ruud M. A.","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1493-7282","authenticated-orcid":false,"given":"Valentina","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben E. E. M.","family":"van den Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0279-9656","authenticated-orcid":false,"given":"Juliette","family":"Degens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-6885","authenticated-orcid":false,"given":"Jarno W. J.","family":"Huijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Pitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Steens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolen","family":"Youssef-El Soud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2214-6492","authenticated-orcid":false,"given":"Martina","family":"Sollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk K. M.","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-957X","authenticated-orcid":false,"given":"Cristina","family":"Mitea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"12","key":"7557_CR1","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","volume":"14","author":"A-MC Dingemans","year":"2019","unstructured":"Dingemans A-MC, et al. Definition of synchronous oligometastatic non\u2013small cell lung cancer\u2014a consensus report. J Thorac Oncol. 2019;14(12):2109\u201319. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.025.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"7557_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","volume":"14","author":"N Giaj-Levra","year":"2019","unstructured":"Giaj-Levra N, et al. Defining synchronous oligometastatic non\u2013small cell lung cancer: a systematic review. J Thorac Oncol. 2019;14(12):2053\u201361. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.037.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"7557_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013.","journal-title":"Ann Oncol"},{"issue":"5","key":"7557_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","volume":"13","author":"P Iyengar","year":"2023","unstructured":"Iyengar P, et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline. Pract Radiat Oncol. 2023;13(5):393\u2013412. https:\/\/doi.org\/10.1016\/j.prro.2023.04.004.","journal-title":"Pract Radiat Oncol"},{"issue":"25","key":"7557_CR5","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"J Clin Oncol"},{"issue":"9","key":"7557_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","volume":"5","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer. JAMA Oncol. 2019;5:1283. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1449.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7557_CR7","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, et al. Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer. JAMA Oncol. 2018;4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501.","journal-title":"JAMA Oncol"},{"issue":"18","key":"7557_CR8","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00201.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7557_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100790","volume":"6","author":"M Jongbloed","year":"2025","unstructured":"Jongbloed M, et al. Impact of immune checkpoint inhibitors and local radical treatment on survival outcomes in synchronous oligometastatic NSCLC. JTO Clin Res Rep. 2025;6(3):100790. https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100790.","journal-title":"JTO Clin Res Rep"},{"issue":"12","key":"7557_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100740","volume":"5","author":"M Jongbloed","year":"2024","unstructured":"Jongbloed M, et al. Prognostic and predictive biomarkers of oligometastatic NSCLC: new insights and clinical applications. JTO Clin Res Rep. 2024;5(12):100740. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100740.","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"7557_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.acra.2011.08.020","volume":"19","author":"S Liao","year":"2012","unstructured":"Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET\/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19(1):69\u201377. https:\/\/doi.org\/10.1016\/j.acra.2011.08.020.","journal-title":"Acad Radiol"},{"issue":"1","key":"7557_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1967\/s002449912444","volume":"25","author":"C Ding","year":"2022","unstructured":"Ding C, et al. Metabolic tumor volume derived from 18F-FDG PET\/CT as a prognostic parameter for non-small cell lung cancer (NSCLC) patients. Hell J Nucl Med. 2022;25(1):63\u201370. https:\/\/doi.org\/10.1967\/s002449912444.","journal-title":"Hell J Nucl Med"},{"key":"7557_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctarc.2017.11.005","volume":"15","author":"K Vanhove","year":"2018","unstructured":"Vanhove K, et al. Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer. Cancer Treatment and Research Communications. 2018;15:7\u201312. https:\/\/doi.org\/10.1016\/j.ctarc.2017.11.005.","journal-title":"Cancer Treatment and Research Communications"},{"key":"7557_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1993","author":"FG Dall\u2019Olio","year":"2024","unstructured":"Dall\u2019Olio FG. Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates. Clin Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1993.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7557_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7557_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"H-J Im","year":"2018","unstructured":"Im H-J, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better?? Nucl Med Mol Imaging. 2018;52(1):5\u201315. https:\/\/doi.org\/10.1007\/s13139-017-0493-6.","journal-title":"Nucl Med Mol Imaging"},{"issue":"9","key":"7557_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","volume":"65","author":"R Boellaard","year":"2024","unstructured":"Boellaard R, et al. International benchmark for total metabolic tumor volume measurement in baseline 18 f-FDG PET\/CT of lymphoma patients: a milestone toward clinical implementation. J Nucl Med. 2024;65(9):1343\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267789.","journal-title":"J Nucl Med"},{"issue":"16_suppl","key":"7557_CR18","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.1200\/JCO.2024.42.16_suppl.8633","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, et al. Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade. J Clin Oncol. 2024;42(16_suppl):8633\u20138633. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8633.","journal-title":"J Clin Oncol"},{"key":"7557_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642883","author":"Y Xu","year":"2021","unstructured":"Xu Y, Li H, Fan Y. Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.642883.","journal-title":"Front Oncol"},{"key":"7557_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","author":"M Reck","year":"2021","unstructured":"Reck M, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2021 50%. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.21.00174.","journal-title":"J Clin Oncol"},{"key":"7557_CR21","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous Non-Small-Cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41:1992\u20138. https:\/\/doi.org\/10.1200\/JCO.22.","journal-title":"J Clin Oncol"},{"key":"7557_CR22","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, et al. Pembrolizumab plus chemotherapy in squamous Non-Small-Cell lung cancer: 5-Year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41:1999\u20132006. https:\/\/doi.org\/10.1200\/JCO.22.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7557_CR23","first-page":"1908","volume":"16","author":"C Perisano","year":"2012","unstructured":"Perisano C, et al. Soft tissue metastases in lung cancer: a review of the literature. Eur Rev Med Pharmacol Sci. 2012;16(14):1908\u201314.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"7557_CR24","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00259-017-3753-x","volume":"44","author":"A Salavati","year":"2017","unstructured":"Salavati A, et al. Optimal FDG PET\/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668\/RTOG 0235 trial. Eur J Nucl Med Mol Imaging. 2017;44(12):1969\u201383. https:\/\/doi.org\/10.1007\/s00259-017-3753-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"7557_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174380","volume":"15","author":"H Lee","year":"2023","unstructured":"Lee H, et al. Prognostic significance of volumetric parameters based on FDG PET\/CT in patients with lung adenocarcinoma undergoing curative surgery. Cancers (Basel). 2023;15(17):4380. https:\/\/doi.org\/10.3390\/cancers15174380.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7557_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00259-016-3520-4","volume":"44","author":"JG Bazan","year":"2017","unstructured":"Bazan JG, et al. Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668\/RTOG 0235. Eur J Nucl Med Mol Imaging. 2017;44(1):17\u201324. https:\/\/doi.org\/10.1007\/s00259-016-3520-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7557_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00259-019-4270-x","volume":"46","author":"M Guberina","year":"2019","unstructured":"Guberina M, et al. Pretreatment metabolic tumour volume in stage IIIA\/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. Eur J Nucl Med Mol Imaging. 2019;46(7):1439\u201347. https:\/\/doi.org\/10.1007\/s00259-019-4270-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7557_CR28","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00259-019-04348-x","volume":"46","author":"M Jreige","year":"2019","unstructured":"Jreige M, et al. 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2019;46(9):1859\u201368. https:\/\/doi.org\/10.1007\/s00259-019-04348-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7557_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2019.03.009","volume":"135","author":"D De Ruysscher","year":"2019","unstructured":"De Ruysscher D, et al. Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-year results of a prospective study. Radiother Oncol. 2019;135:141\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2019.03.009.","journal-title":"Radiother Oncol"},{"issue":"1","key":"7557_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-022-00154-3","volume":"7","author":"JG Holler","year":"2022","unstructured":"Holler JG, Renm\u00e6lmo B, Fjellaksel R. Stability evaluation of [18F]FDG: literature study, stability studies from two different PET centres and future recommendations. EJNMMI Radiopharm Chem. 2022;7(1):2. https:\/\/doi.org\/10.1186\/s41181-022-00154-3.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"7557_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.radonc.2010.10.006","volume":"98","author":"M Wanet","year":"2011","unstructured":"Wanet M, et al. Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. Radiother Oncol. 2011;98(1):117\u201325. https:\/\/doi.org\/10.1016\/j.radonc.2010.10.006.","journal-title":"Radiother Oncol"},{"issue":"1","key":"7557_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jrr\/rrw082","volume":"58","author":"K Ikushima","year":"2017","unstructured":"Ikushima K, et al. Computer-assisted framework for machine-learning\u2013based delineation of GTV regions on datasets of planning CT and PET\/CT images. J Radiat Res. 2017;58(1):123\u201334. https:\/\/doi.org\/10.1093\/jrr\/rrw082.","journal-title":"J Radiat Res"},{"issue":"4","key":"7557_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1470-2045(24)00040-8","volume":"25","author":"BHL Goulart","year":"2024","unstructured":"Goulart BHL, et al. Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis. Lancet Oncol. 2024;25(4):455\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00040-8.","journal-title":"Lancet Oncol"},{"key":"7557_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02948-z","author":"X Lin","year":"2025","unstructured":"Lin X, et al. Intratumoral and peritumoral PET\/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC. Br J Cancer. 2025. https:\/\/doi.org\/10.1038\/s41416-025-02948-z.","journal-title":"Br J Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07557-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07557-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:22Z","timestamp":1769834602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07557-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7557"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07557-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Maastricht UMC\u2009+\u2009institutional review board (2021\u20132973) and the local IRBs of the participating hospitals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived by Maastricht UMC\u2009+\u2009institutional review board (2021\u20132973) and the local IRBs of the participating hospitals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"FO received fees as speaker from Roche Genentech, Sanofi, Amgen, and travel support from Amgen, Johnson&Johnson.MS received speaker honoraria from Elma academy, Train srl, Accademia nazionale di medicina, GE Healthcare, and serves as associate editor of Cancer Imaging for the \u201cArtificial intelligence, machine learning and radiomics\u201d section.DDR received research grants, financial supports and\/or participated at advisory boards of AstraZeneca, BMS, Beigene, Philips, Olink, Eli-Lilly; all should be considered institutional financial interests (not personal).LH received research funding from Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Novartis, Gilead; all payments were paid to the institution. LH received fees as speaker at educationals or webinars from AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, Janssen, GSK, Sanofi, Pfizer (Inst), Medtalks, Benecke, VJOncology, Medimix; all payments were paid to the institution with the exception of Medtalks, Benecke, VJOncology, Medimix. LH participated at advisory boards of Abbvie, Amgen, Anhearth, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Summit Therapeutics, Takeda; all payments were paid to the institution. LH is member of guideline committees for Dutch guidelines on NSCLC, brain metastases and leptomeningeal metastases (payment to self), ESMO guidelines on metastatic NSCLC, non-metastatic NSCLC and SCLC (non-financial); other roles: secretary NVALT studies foundation, subchair EORTC metastatic NSCLC systemic therapy, vice-chair scientific committee Dutch Thoracic Group. LH is local principal investigator of clinical trials funded by AstraZeneca, GSK, Novartis, Merck, Roche, Takeda, Blueprint, Mirati, Abbvie, Gilead, MSD, Merck, Amgen, Boehringer Ingelheim, Pfizer.The other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}